Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio-Rad Receives Award for QX100 Droplet Digital PCR System

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
Company receives Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future market leader of digital PCR technology award.

Bio-Rad Laboratories, Inc. has announced that it has received the Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future Market Leader of Digital PCR Technology Award, for its QX100™ Droplet Digital™ PCR system.

This annual award is given to a company that has demonstrated excellence and distinguished itself through proactive strategies that position the company as an industry leader.

In a study titled 2012 Quantitative and Digital PCR Instrumentation and Consumables Purchasing Trends, the global growth consulting company Frost & Sullivan reported that 56% of healthcare-related laboratory decision makers in North America said they plan to install the QX100 Droplet Digital PCR system in their labs within the next 12 months.

This product choice is significantly higher than for any other digital PCR system, positioning the QX100 system as a potential future leader in the digital PCR market segment.

“The high sensitivity of digital PCR makes it ideal for a growing number of applications, including copy number variation, rare mutation detection, and absolute quantification of nucleic acid sequences,” said Frost & Sullivan research analyst Karolina Olszewska.

Olszewska continued, “In this high-growth, promising market, we believe Bio-Rad’s investment in digital PCR will prove to be fruitful and they will be a future leader in this market segment.”

Droplet Digital PCR Shows Promise in Diagnostics and Personalized Medicine
Digital PCR is generating increasing attention in the industry for its potential in diagnostic and pharmaceutical applications. Researchers at Sangamo BioSciences have been using the QX100 system to develop therapies and potentially a cure for HIV.

“The QX100 system allowed us to easily, accurately, and reproducibly measure low-copy events in genomic DNA,” said Dr. Gary Lee, senior scientist at Sangamo BioSciences. “We have been able to demonstrate that it is the technology of choice when it comes to rare event detection applications, particularly in clinical studies.”

Researchers in the Ji Laboratory at Stanford University have also observed the benefits of the QX100 system. This group uses the system to accurately and precisely measure cancer genome amplifications in archival cancer tissue samples.

Their work targeting these amplified oncogenes could ultimately lead to personalized therapies for cancer treatment.

Frost & Sullivan expects the U.S. dPCR instrumentation market to grow 52% from 2011 to 2016. They believe the QX100 system will emerge as a leader in the digital PCR platform on the market due to the system’s precision, simple workflow, and affordability.

Bio-Rad will be honored with this recognition at Frost & Sullivan’s 2012 Excellence in Best Practices Awards Banquet on March 12.

The event recognizes companies, strategies, processes, and executives that have achieved world-class performance within their industries.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bio-Rad QX200 ddPCR System Recieves CE IVD Mark
The first digital PCR instrument with the CE IVD mark.
Monday, February 29, 2016
Presentations at the AACR Annual Meeting to Highlight Advances in Cancer Research Made Possible by Bio-Rad’s Droplet Digital™ PCR Technology
Tailoring Treatments and Tracking Mutations with Liquid Biopsies possible with ddPCR™ technology
Wednesday, April 22, 2015
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad Acquires QuantaLife and Digital PCR Technology
Bio-Rad purchases QuantaLife for $162 million in cash plus potential future milestone payments.
Friday, October 07, 2011
Bio-Rad to Report Fourth-Quarter and Full-Year 2010 Financial Results Thursday, February 24, 2011
Company will discuss the results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Monday, March 14, 2011
Bio-Rad Reports Record Fourth-Quarter and Full-Year 2010 Financial Results
Fourth-quarter reported revenues were $533.7 million, up 7.8% compared to $495.1 million reported for the fourth quarter of 2009.
Monday, February 28, 2011
Bio-Rad Announces Public Offering of $425 Million Senior Notes
The interest rate and other terms of the Senior Notes are to be determined by negotiations between the Company and the underwriters of the Senior Notes.
Tuesday, December 07, 2010
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos